In the landscape of medical research, equity, diversity, and inclusivity (EDI) are not merely buzzwords but guiding principles that shape the trajectory of progress. Nowhere is this more apparent than in the realm of gynecologic cancer clinical trials, where the pursuit of equitable healthcare access intersects with the complexities of patient diversity.